Michael A. Cannarile

Roche Pharma AG (Germany) — Germany

Medicine · Health Sciences

23h-index4.6kcitations72works4.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(37), Immune cells in cancer(25), Immunotherapy and Immune Responses(18), Immune Cell Function and Interaction(12), Cancer Genomics and Diagnostics(8)

Publications72 total

Molecular subtypes of hepatocellular carcinoma linked to liver cell lineages and clinical outcomes of combination immunotherapy
Cell Reports Medicine·2025Open Access
151P Enhanced pharmacodynamic effects upon combination of cibisatamab and FAP-4-1BBL in 3L+ mMSS CRC patients
Annals of Oncology·2024· 1 citedOpen Access
Tumor-agnostic transcriptome-based classifier identifies spatial infiltration patterns of CD8+T cells in the tumor microenvironment and predicts clinical outcome in early-phase and late-phase clinical trials
Journal for ImmunoTherapy of Cancer·2024· 12 citedOpen Access
Facts and Hopes on Biomarkers for Successful Early Clinical Immunotherapy Trials: Innovative Patient Enrichment Strategies
Clinical Cancer Research·2023· 1 cited
Tumor-agnostic transcriptome-based classifier identifies spatial infiltration patterns of CD8+ T cells in the tumor microenvironment and predicts clinical outcome in early- and late-phase clinical trials
2023Open Access
Abstract CT096: Phase 1 study of RO7119929 (TLR7 agonist prodrug) in patients (pts) with advanced primary or metastatic liver cancers
Cancer Research·2023· 4 cited
Abstract 2342: RO7119929, a TLR7 agonist prodrug, induces local inflammation of the tumor microenvironment (TME) by reprogramming myeloid cells in patients (pts) with advanced primary or metastatic liver cancers
Cancer Research·2023· 2 cited
Figure S5 from Macrophage Susceptibility to Emactuzumab (RG7155) Treatment
2023Open Access
Figure S1 from Macrophage Susceptibility to Emactuzumab (RG7155) Treatment
2023Open Access
Data from Macrophage Susceptibility to Emactuzumab (RG7155) Treatment
2023Open Access
Figure S3 from Macrophage Susceptibility to Emactuzumab (RG7155) Treatment
2023Open Access
Figure S1 from Macrophage Susceptibility to Emactuzumab (RG7155) Treatment
2023Open Access
Supplementary information from Macrophage Susceptibility to Emactuzumab (RG7155) Treatment
2023Open Access
Figure S6 from Macrophage Susceptibility to Emactuzumab (RG7155) Treatment
2023Open Access
Figure S5 from Macrophage Susceptibility to Emactuzumab (RG7155) Treatment
2023Open Access
Figure S3 from Macrophage Susceptibility to Emactuzumab (RG7155) Treatment
2023Open Access
Figure S6 from Macrophage Susceptibility to Emactuzumab (RG7155) Treatment
2023Open Access
Figure S4 from Macrophage Susceptibility to Emactuzumab (RG7155) Treatment
2023Open Access
Supplementary information from Macrophage Susceptibility to Emactuzumab (RG7155) Treatment
2023Open Access
Data from Macrophage Susceptibility to Emactuzumab (RG7155) Treatment
2023Open Access
page 1 of 4Next →

Frequent Co-authors

Carola H. Ries(23), Dominik Rüttinger(20), Jean‐Pierre Delord(13), Christophe Le Tourneau(12), Philippe A. Cassier(10), Chia-Huey Ooi(10), Leon P. Pradel(9), Irina Klaman(9), Solange Romagnoli(9), Sabine Hoves(8), Hadassah Sade(8), Valeria Runza(7), Antoîne Italiano(7), Jean‐Yves Blay(7), Anna-Maria Jegg(7), Georgina Meneses‐Lorente(7), R D Christen(7), Konstanty Korski(7), K. Abiraj(6), Carlos Gomez-Roca(6)